Data completeness
2/8 — Basic
NICLOCIDE (niclosamide) by R-Pharm US. Approved for covid-19, ulcerative colitis, intestinal parasitism and 1 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NICLOCIDE (niclosamide) is an oral anthelmintic tablet approved by the FDA for treatment of intestinal parasitism and tapeworm infections, with emerging clinical investigation in COVID-19 and ulcerative colitis. The drug works by disrupting mitochondrial oxidative phosphorylation in parasites, leading to their elimination. Niclosamide represents a repurposing strategy leveraging an older anthelmintic mechanism for novel therapeutic applications.
Pre-Launch
Early-stage product with limited commercial infrastructure; team building and market development roles likely expanding as clinical data matures.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on NICLOCIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.